Ukr.Biochem.J. 2026; Volume 98, Issue 1, Jan-Feb, pp. 69-77

doi: https://doi.org/10.15407/ubj98.01.069

OCT4 immunostaining is associated with breast cancer grade and tumor size

11.02.2026   Uncategorized

D. A. Alghezi

Department of Microbiology, College of Medicine, University of Thi-Qar, Thi-Qar, Iraq;
e-mail: Dr.daf79@utq.edu.iq; Dhafer.a.f.alghezi@bath.edu

Received: 25 August 2025; Revised: 09 December 2025;
Accepted: 30 January 2026; Available on-line: 23 February 2026

Breast cancer remains one of the most prevalent tumors among females worldwide, and current prognostic methods are limited in their ability to accurately predict tumor aggressiveness. Octamer-binding transcription factor 4 (Oct4), a key regulator of pluripotency and cancer stem cell characteristics, has emerged as a promising biomarker in various cancers. This study aimed to evaluate the results of Oct4 immunostaining in benign and malignant breast tissues and its link with cancer grade and tumor size. The archival formalin-fixed breast tissue specimens, comprising 110 breast carcinoma and 20 benign tumors were examined. Oct4 expression was assessed immunohistochemically using a rabbit monoclonal anti-Oct4 antibody. The study demonstrated a significant increase in nuclear Oct4 staining in malignant breast cancer tissues compared to benign tumors. Elevated Oct4 immunostaining was positively associated with high grade and larger tumor size. However, no significant correlation was observed between Oct4 level and lymph node status. Thus, ele­vated Oct4 expression is associated with higher tumor grade and larger tumor size, suggesting its potential relevance in breast cancer progression.

Keywords: , , ,

References:

  1. Abdelaziz LA, Ebian HF, Harb OA, Nosery Y, Taha HF, Nawar N. Clinical significance of cytokeratin 19 and OCT4 as survival markers in non-metastatic and metastatic breast cancer patients. Contemp Oncol (Pozn). 2022;26(1):78-87. PubMed, PubMedCentral, CrossRef
  2. Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q, Liu X, Duan H, Feng Z, Liu Y, Zhang Y, Lyu Z, Song F, Song F, Yang L, Liu H, Huang Y. Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Cent. 2025;5(3):287-296. PubMed, PubMedCentral, CrossRef
  3. GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204-2256. PubMed, PubMedCentral, CrossRef
  4. Salih HH, Abd SY, Al-Kaseer E, Al-Diwan J. Cancer in Iraq, general view of annual report 2022. J Contemp Med Sci. 2025;10(6):475-477. CrossRef
  5.  ICR. Cancer registry of Iraq annual report. 2022.
  6. Alghezi DA, Aljawher R, Mosa HN. Increased KI67 Immunostaining is Associated with Breast Cancer Aggressiveness. J Cancer Res Updat. 2025;14:170-180. CrossRef
  7. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-3158. PubMed, CrossRef
  8. Popa MT, Nodiţi A, Peleaşă TM, Stoleru S, Blidaru A. Breast Cancer: A Heterogeneous Pathology. Prognostic and Predictive Factors – A Narrative Review. Chirurgia (Bucur). 2025;120(1):32-47. PubMed, CrossRef
  9. Alghezi DA, P W, BeresfordM, R B, J M, D CA. Reduced β-catenin immunostaining in prostate cancer and negatively associated with poorly differentiated Gleason grades. Kerbala J Pharm Pharmaceut Sci. 2021;1(19):179-195.
  10. Alghezi DA, Aljawher R, Alsaadi E. Increased Sox2 immunostaining in prostate cancer and associated with Gleason score and stage. Bull Nat Institute Health Sci. 2022;140(4):2423-2431.
  11. Alghezi D, Aljawher R, Al-Musawi S. Increased CD73 expression is associated with poorly differentiated Gle ason score and tumor size in prostate cancer. J Adv Biotechnol Exp Ther. 2023;6(1):161-171. CrossRef
  12. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. PubMed, CrossRef
  13. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5):499-507. PubMed, PubMedCentral, CrossRef
  14. Wang YJ, Herlyn M. The emerging roles of Oct4 in tumor-initiating cells. Am J Physiol Cell Physiol. 2015;309(11):C709-C718. PubMed, PubMedCentral, CrossRef
  15. Wang D, Lu P, Zhang H, Luo M, Zhang X, Wei X, Gao J, Zhao Z, Liu C. Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget. 2014;5(21):10803-10815. PubMed, PubMedCentral, CrossRef
  16. Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Schöler H, Smith A. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 1998;95(3):379-391. PubMed, CrossRef
  17. Alalwany O, Alghezi DA, Aljawher RQ, Harb A. Increased CD3 immunostaining associated with high grade and tumor size in colorectal carcinoma. Egypt J Med Microbiol. 2025;34(1):205-212. CrossRef
  18. Robinson L, Smit C, van Heerden MB, Moolla H, Afrogheh AH, Opperman JF, Ambele MA, van Heerden WFP. Surrogate Immunohistochemical Markers of Proliferation and Embryonic Stem Cells in Distinguishing Ameloblastoma from Ameloblastic Carcinoma. Head Neck Pathol. 2024;18(1):92. PubMed, PubMedCentral, CrossRef
  19. Li J, Chen Z, Su K, Zeng J. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol. 2015;8(7):8500-8505. PubMed, PubMedCentral
  20. Teichgraeber DC, Guirguis MS, Whitman GJ. Breast Cancer Staging: Updates in the AJCC Cancer Staging Manual, 8th Edition, and Current Challenges for Radiologists, From the AJR Special Series on Cancer Staging. AJR Am J Roentgenol. 2021;217(2):278-290. PubMed, CrossRef
  21. Chen W, Dong J, Haiech J, Kilhoffer MC, Zeniou M. Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy. Stem Cells Int. 2016;2016:1740936. PubMed, PubMedCentral, CrossRef
  22. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124-1134. PubMed, CrossRef
  23. Alghezi DA, Harb A. Elevated Sall4 Expression Correlates with Prostate Cancer Gleason Score and Metastasis using Immunohistochemistry and RNAscope®. J Assoc Med Sci. 2026;59(2):24-33. CrossRef
  24. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000;24(4):372-376. PubMed, CrossRef
  25. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008;14(13):4085-4095. PubMed, CrossRef
  26. Kim JS, Lee JH, Yeon Y, An D, Kim SJ, Noh MG, Lee S. Predicting Nottingham grade in breast cancer digital pathology using a foundation model. Breast Cancer Res. 2025;27(1):58. PubMed, PubMedCentral, CrossRef
  27. Ellsworth RE, Hooke JA, Love B, Ellsworth DL, Shriver CD. Molecular changes in primary breast tumors and the Nottingham Histologic Score. Pathol Oncol Res. 2009;15(4):541-547. PubMed, CrossRef
  28. Abou Gabal HH, Abu-Zeid RM, El-Maraghy MN. Implications of OCT4 in breast carcinoma from initiation to lymph node metastasis: an immunohistochemical study. Egypt J Patholy. 2016;36(2):194-200. CrossRef
  29. Liu T, Sun B, Zhao X, Li Y, Gu Q, Dong X, Liu F. OCT4 expression and vasculogenic mimicry formation positively correlate with poor prognosis in human breast cancer. Int J Mol Sci. 2014;15(11):19634-19649.
    PubMed, PubMedCentral, CrossRef
  30. Fritz K, Salavastru C. The 308 nm Excimer laser : Treatment of vitiligo and hypopigmentation. Hautarzt. 2018;69(1):44-47. PubMed, CrossRef
  31. Yang F, Zhang J, Yang H. OCT4, SOX2, and NANOG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2+ breast cancer patients. Onco Targets Ther. 2018;11:7873-7881. PubMed, PubMedCentral, CrossRef
  32. Soheili S, Asadi MH, Farsinejad A. Distinctive expression pattern of OCT4 variants in different types of breast cancer. Cancer Biomark. 2017;18(1):69-76. PubMed, CrossRef
  33. Joshi GR, Patel NA, Vora HH. Clinical significance of Aldh1a1, Cd133 and Oct 4 in breast cancer and its association with epithelial mesenchymal transition. J Genet Mutat. 2018;1(2):15-20.
  34. Gwak JM, Kim M, Kim HJ, Jang MH, Park SY. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance. Oncotarget. 2017;8(22):36305-36318. PubMed, PubMedCentral, CrossRef
  35. Zhang JM, Wei K, Jiang M. OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer. Breast Cancer. 2018;25(4):447-455. PubMed, CrossRef
  36. Chen ZS, Ling DJ, Zhang YD, Feng JX, Zhang XY, Shi TS. Octamer-binding protein 4 affects the cell biology and phenotypic transition of lung cancer cells involving β-catenin/E-cadherin complex degradation. Mol Med Rep. 2015;11(3):1851-1858. PubMed, CrossRef
  37. Immunocytochemical methods and protocols. Eds. Oliver C, Jamur MC. Humana Totowa, NJ, 2010. 588 p. CrossRef
  38. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1):22-29. PubMed, PubMedCentral, CrossRef
  39. Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. Alterations in beta-catenin expression and localization in prostate cancer. Prostate. 2008;68(11):1196-1205. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.